drugset
drugset / Trial / NCT04514484

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04514484 ↗

Phase 1 Active not recruiting 8 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.

Timeline

Start
2021-11-22
Primary completion
2024-11-11
Completion
2027-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule — Oral
Subject Nivolumab Monoclonal antibody — Intravenous

Indications

HIV infectious disease Kaposi's sarcoma castration-resistant prostate carcinoma cutaneous melanoma female breast carcinoma head and neck carcinoma hepatocellular carcinoma high grade malignant neoplasm medullary thyroid gland carcinoma metastatic malignant neoplasm metastatic melanoma metastatic prostate carcinoma non-small cell lung carcinoma ovarian carcinoma renal cell carcinoma small cell lung carcinoma triple-negative breast carcinoma urothelial carcinoma